Investor News Source Issues Press Coverage on EastGate Acquisition's Latest Announcement

NEW YORK - Nov. 3, 2014 - PRLog -- The global neutracutical market is forecast to show growth in excess of 7% this year to reach almost $24 billion in 2015 according to research from Freedonia, the company that conducted the independent research report where I got these numbers... The study finds that the greatest growth will come from the sale of products that use ingredients with clinically confirmed health benefits. These compounds are used in a wide rang of dietary supplements, drinks, foods, and nutritional preparations for children and adults alike. Here is where things get interesting for Today's pick... ESAQ.

Just to give you a little insight to the industry for both pharmaceutical products and natural supplements, they are developed using highly effective contemporary technologies and have demonstrated to be proven useful in improvement of bioavailability and biological action of incorporated molecules by combining pre-approved compounds. It's a mouth full I know but What that means is that ESAQ has developed ways for pharma and nutraceutical products to be more effective in treating specific ailment.  These include diabetes, epilepsy, and even body cleanses.  Most recently the company has focused on different, non invasive ways to deliver medication for diabetes and epilepsy.

In fact this morning the company announced that it will be presenting its proprietary Lorazapam Spray at the American Association of Pharmaceutical Scientists (AAPS) Conference.  There will be thousands in attendance and hundreds of other exhibitors walking the aisles.  EastGate's Lorazepam spray has been catching attention more recently and this could be a great opportunity for ESAQ to gain more exposure for potential customers and in becoming a possible acquisition or JV target.

Let's speculate here for a moment;

PDL BioPharma, Inc. acquired the rights to receive royalties and milestones payable on sales of Type 2 diabetes products licensed by Depomed in exchange for a $240.5 million cash payment.

Johnson & Johnson agreed to acquire Inverness Medical Technology Inc. 's diabetes-care-products business for about $1.3 billion.

AstraZeneca will pay $2.7 billion upfront and as much as $1.4 billion more to Bristol-Myers Squibb Co. for its diabetes-treatment business depending on regulatory, commercial and sales goals.

Carlyle Group LP agreed to buy the Ortho Clinical unit of Johnson & Johnson for $4.15 billion, a deal that would shed the health-care products company's only diagnostics division noting that the company's diabetes business "may be the target of future strategic alternatives."

With that being said, the Buzz has been building on Today's Pick and hopefully everyone who is trading the stock today has read the report from last night.  One thing I didn't mention in the report is that of the 50,000,000 shares of common stock that are issued and outstanding the float is LESS THAN 3 MILLION shares. That's super low in my opinion and the L2 is tight. A perfect formula for profit!

I've already begun to see that there are other lists that are trying to coat tail...Twitter is humming and there are several people right now hyping this up in the skype chat rooms. Do not miss ESAQ on the first day, you might hate yourself later. It's time to get down to business and get ready for ESAQ.  The opening bell is less than an hour away!  Check out this morning's news, read through last night's report, and let's kick off the first week of November with a bang.

Today's News

EastGate Acquisitions Announces Poster Presentation Of The Company's Proprietary Intraoral Lorazepam Spray At The American Association of Pharmaceutical Scientists (AAPS) Conference


SALT LAKE CITY and TORONTO, Nov. 3, 2014 /PRNewswire/ -- EastGate Acquisitions Corporation , an emerging pharmaceutical company exploring drug delivery innovations for the development of novel formulations and alternative dosage forms of existing biologically active molecules announces a poster presentation of its proprietary intraoral lorazepam spray at the American Association of Pharmaceutical Scientists (AAPS) Conference.
The AAPS conference is held at the San Diego Convention Center until November 6, 2014 in San Diego, California.

The abstract entitled "Lorazepam Oral Spray for Epileptic Emergency Treatment" (Poster # M1204) will be presented by the company's Chief Medical Officer Dr. Michael Weisspapir and the company's Chief Scientific Officer, Dr. Joseph Schwarz on Monday, November 3rd. The session time for the poster presentation is between 1:30 p.m. 5:00 p.m. at the San Diego Convention Center Halls B-F.

The poster authored by Drs. Joseph Schwarz, Michael Weisspapir, Peter Carlen present the results of an animal study utilizing the company's intraoral transmucosal Lorazepam, in a proprietary self-nanoemulsifying drug delivery (SNEDDS). Lorazepam SNEDDS, administered to mice intraorally 3 or 5 minutes before the start of a PTZ infusion showed anticonvulsant efficacy comparable to parenteral administration of Lorazepam injectable solution. The conclusions of the study was that a Lorazepam intraoral spray may be a safe, convenient and rapid acting formulation that can be developed and applied for both hospital and out-of-hospital settings. A high drug loading 0.5 mg of Lorazepam in a single actuation (50 microliters) allows for easy and effective dose adjustment. The Lorazepam intraoral spray development is likely to satisfy requirement for a 505 (b)(2) regulatory pathway in the USA or the hybrid pathway in Europe.

The intraoral Lorazepam Spray provides a non-invasive method for the treatment of acute and repetitive seizures. This spray delivers a low volume, oral anti-convulsant formulation designed to be a quick and effective treatment of acute seizures in hospital, home or ambulatory settings. This oral spray of the potent anticonvulsant is an exceptionally convenient alternative to injectable benzodiazepines that efficiently control epilepsy emergencies. The intraoral spray formulation can be used by the patient, paramedics, or any other available non-trained persons, even during the ongoing seizures.

"We are pleased to have the opportunity to present our innovative intraoral Lorazepam Spray at the AAPS conference", says Anna Gluskin, EastGate's CEO. "Lorazepam is a well-known drug and our very own sub-micron self-nanoemulsifying drug delivery platform will make this a safe, effective and easy-accessible treatment for epileptic patients, both adults and children." "The company anticipates that it will pursue the 505(b)(2) regulatory pathway in order to expedite this development", says Gluskin.

Disclaimer: http://www.investornewssource.com